Comment on “Serum human epididymis protein 4 is associated with the treatment response of concurrent chemo-radiotherapy and prognosis in patients with locally advanced non-small cell lung cancer” by Lan WG et al.

被引：0
|
作者：
G. Yavas
C. Yavas
S. Akyurek
机构：
[1] Selcuk University,Department of Radiation Oncology
[2] Ankara University,Department of Radiation Oncology
来源：
Clinical and Translational Oncology | 2018年 / 20卷
关键词：
Serum HE4; Human Epididymis Protein 4 (HE4); Concurrent Chemoradiotherapy; Shorter RFS; Smoking Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：801 / 802
页数：1
相关论文
共 50 条
  • [1] Serum human epididymis protein 4 is associated with the treatment response of concurrent chemo-radiotherapy and prognosis in patients with locally advanced non-small cell lung cancer
    Yavas, G.
    Yavas, C.
    Akyurek, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 801 - 802
  • [2] Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer
    Lan, W-G.
    Hao, Y-Z.
    Xu, D-H.
    Wang, P.
    Zhou, Y-L.
    Ma, L-B.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (04): : 375 - 380
  • [3] Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer
    W.-G. Lan
    Y.-Z. Hao
    D.-H. Xu
    P. Wang
    Y.-L. Zhou
    L.-B. Ma
    Clinical and Translational Oncology, 2016, 18 : 375 - 380
  • [4] Prognostic Significance of Serum Human Epididymis Protein 4 Level in Patients with Locally Advanced Non-Small Cell Lung Cancer who Underwent Definitive Chemo-Radiotherapy
    Yavas, Guler
    Birgi, Sumerya Duru
    Unlu, Ali
    Yavas, Cagdas
    Duzova, Mursel
    Akyurek, Serap
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2022, 32 (02): : 126 - 132
  • [5] Use of chemo-radiotherapy in locally advanced non-small cell lung cancer
    Novello, S
    Le Chevalier, T
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (02) : 292 - 299
  • [6] Immunological Biomarkers Characterization in Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemo-Radiotherapy
    Saigi, M.
    Baixeras, N.
    Rullan, A.
    Bergamino Sirven, M.
    Navarro-Martin, A.
    Arnaiz, M.
    Ruffinelli, J. C.
    Mesia, C.
    Palmero, R.
    Padrones, S.
    Cardenal, F.
    Sanchez-Cespedes, M.
    Nadal, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2155 - S2155
  • [7] Managing the care of patients receiving concurrent chemo-radiotherapy for non-small cell lung cancer-lan overview
    Halkyard, E.
    Fenemore, J.
    LUNG CANCER, 2012, 75 : S34 - S35
  • [8] Concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer (NSCLC): A multicenter randomized phase II study
    Bouillet, T
    Diana, C
    Pailler, M
    Gozy, M
    Labrune, S
    Gervais, R
    Brechot, J
    Breau, J
    Chinet, T
    Morere, J
    LUNG CANCER, 2005, 49 : S166 - S167
  • [9] Pre-treatment serum albumin is a prognostic biomarker for locally advanced non-small cell lung cancer: extended follow up of patients treated with concurrent chemo-radiotherapy
    Killean, Angus
    Horne, Ashley
    Phillips, Iain
    Maclennan, Kirsty
    Evans, Tamasin
    Little, Felicity
    Tufail, Aisha
    Stares, Mark
    LUNG CANCER, 2021, 156 : S3 - S4
  • [10] Optimal chemotherapy regimen for concurrent chemo-radiotherapy of locally advanced unresectable stage III non-small cell lung cancer (NCSLC)
    Jokhadze, N.
    Kiladze, I.
    Katselashvili, L.
    Kacharava, M.
    Jankarashvili, N.
    Zumbadze, I.
    Kalandarishvili, N.
    Melkadze, T.
    Gogua, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S66 - S67
12345